Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fa-Po Chung

Showing results (81-90 of 292) with videos related to

Pageof 30
Sort By:
ESC Heart Failure|August 10, 2022
Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapyHsin-Ti Huang, Jin-Long Huang, Po-Lin Lin, et al.
Frontiers in Cardiovascular Medicine|August 12, 2022
Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartanChien-Yi Hsu, Hung-Yu Chang, Chieh-Ju Chao, et al.
Journal of Cardiovascular Electrophysiology|February 27, 2013
Differences in the atrial electrophysiological properties between vagal and sympathetic types of atrial fibrillationLi-Wei Lo, Chuen-Wang Chiou, Yenn-Jiang Lin, et al.
Stroke|July 11, 2019
Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial FibrillationWen-Han Cheng, Tze-Fan Chao, Yenn-Jiang Lin, et al.
Acta Cardiologica Sinica|September 30, 2022
Nonlinear Heart Rate Dynamics Before and After Paroxysmal Atrial Fibrillation EventsTing-Wei Ernie Liao, Li-Wei Lo, Yenn-Jiang Lin, et al.
International Journal of Cardiology|February 7, 2018
Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort studyTze-Fan Chao, Gregory Y H Lip, Yenn-Jiang Lin, et al.
European Heart Journal|January 4, 2019
Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbiditiesTze-Fan Chao, Gregory Y H Lip, Yenn-Jiang Lin, et al.
Mayo Clinic Proceedings|March 26, 2024
Efficacy of Sacubitril-Valsartan on Survival and Cardiac Remodeling in Hypotensive Heart Failure With Reduced Ejection Fraction: A Multicenter StudyChien-Yi Hsu, Fa-Po Chung, Chieh-Ju Chao, et al.
Thrombosis and Haemostasis|March 7, 2018
Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk FactorsTze-Fan Chao, Gregory Y H Lip, Yenn-Jiang Lin, et al.
Thrombosis and Haemostasis|March 23, 2019
Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' PatientsTze-Fan Chao, Jo-Nan Liao, Ta-Chuan Tuan, et al.
Pageof 30

Showing results (81-90 of 292) with videos related to

Sort By:
Pageof 30
ESC Heart Failure|August 10, 2022
Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapyHsin-Ti Huang, Jin-Long Huang, Po-Lin Lin, et al.
Frontiers in Cardiovascular Medicine|August 12, 2022
Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartanChien-Yi Hsu, Hung-Yu Chang, Chieh-Ju Chao, et al.
Journal of Cardiovascular Electrophysiology|February 27, 2013
Differences in the atrial electrophysiological properties between vagal and sympathetic types of atrial fibrillationLi-Wei Lo, Chuen-Wang Chiou, Yenn-Jiang Lin, et al.
Stroke|July 11, 2019
Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial FibrillationWen-Han Cheng, Tze-Fan Chao, Yenn-Jiang Lin, et al.
Acta Cardiologica Sinica|September 30, 2022
Nonlinear Heart Rate Dynamics Before and After Paroxysmal Atrial Fibrillation EventsTing-Wei Ernie Liao, Li-Wei Lo, Yenn-Jiang Lin, et al.
International Journal of Cardiology|February 7, 2018
Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort studyTze-Fan Chao, Gregory Y H Lip, Yenn-Jiang Lin, et al.
European Heart Journal|January 4, 2019
Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbiditiesTze-Fan Chao, Gregory Y H Lip, Yenn-Jiang Lin, et al.
Mayo Clinic Proceedings|March 26, 2024
Efficacy of Sacubitril-Valsartan on Survival and Cardiac Remodeling in Hypotensive Heart Failure With Reduced Ejection Fraction: A Multicenter StudyChien-Yi Hsu, Fa-Po Chung, Chieh-Ju Chao, et al.
Thrombosis and Haemostasis|March 7, 2018
Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk FactorsTze-Fan Chao, Gregory Y H Lip, Yenn-Jiang Lin, et al.
Thrombosis and Haemostasis|March 23, 2019
Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' PatientsTze-Fan Chao, Jo-Nan Liao, Ta-Chuan Tuan, et al.
Pageof 30